Harnessing TP73‑targeted nintedanib: A novel strategy to halt triple‑negative breast cancer via p53‑PPAR&alpha;/PI3K‑Akt pathway suppression

Zou,Xiaomeng; Li,Shiyu; Huang,Sisi; Niu,Ruilan; Liu,Gang; Wang,Zhili

doi:10.3892/ijo.2025.5794

Harnessing TP73‑targeted nintedanib: A novel strategy to halt triple‑negative breast cancer via p53‑PPARα/PI3K‑Akt pathway suppression

Authors:
- Xiaomeng Zou
- Shiyu Li
- Sisi Huang
- Ruilan Niu
- Gang Liu
- Zhili Wang
View Affiliations

Affiliations: Department of Ultrasound, The First Medical Center, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China, Department of Radiology, The First Medical Center, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China
Published online on: August 22, 2025 https://doi.org/10.3892/ijo.2025.5794
Article Number: 88
Copyright: © Zou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple‑negative breast cancer (TNBC) is an aggressive malignancy with limited treatment options, leading to poor clinical outcomes and the need for novel therapeutic approaches. Nintedanib, a United States Food and Drug Administration‑approved multi‑kinase inhibitor with anti‑fibrotic and anti‑angiogenic properties, has shown promise in cancer treatment. However, its precise molecular effects on TNBC have not yet been fully elucidated. Therefore, the present study aimed to investigate the therapeutic potential of nintedanib in TNBC using in vitro and in vivo models, specifically focusing on its regulatory effects on key oncogenic pathways. The present study utilized TNBC cell lines (MDA‑MB‑231 and 4T1) and BALB/c mice to evaluate the antitumor efficacy of nintedanib. Cell viability and clonogenic capacity were assessed using Cell Counting Kit‑8 and colony formation assays. Subsequently, apoptosis induction and cell cycle progression were determined by flow cytometry, and cell migration and invasion were analyzed through scratch and Transwell assays. To identify underlying mechanisms, potential molecular targets were identified via bioinformatics and network pharmacology, and were validated through western blotting, immunofluorescence and immunohistochemistry. Finally, an orthotopic TNBC mouse model was established and monitored in real time by multimodal ultrasound imaging. The results revealed that nintedanib significantly inhibited TNBC cell proliferation and suppressed stem cell‑like properties. Furthermore, it induced cell cycle arrest at the G₂/M phase and promoted apoptosis. Mechanistic analysis revealed that nintedanib activated tumor protein p73 (TP73), leading to the disruption of the p53‑peroxisome proliferator‑activated receptor α (PPARα)/PI3K‑Akt signaling axis. Additionally, it downregulated epithelial‑mesenchymal transition (EMT) markers, including Snail and zinc finger E‑box‑binding homeobox protein 1, thereby mitigating tumor invasiveness. In vivo, nintedanib treatment effectively reduced tumor growth, angiogenesis and stiffness, indicating its potential as a viable therapeutic agent for TNBC. In conclusion, nintedanib exerts potent anti‑TNBC effects by modulating TP73, disrupting oncogenic signaling via the p53‑PPARα/PI3K‑Akt axis, and attenuating EMT‑associated transcription factors. These findings highlight its potential as a promising targeted therapy for TNBC, warranting further clinical exploration.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI
2	Nolan E, Lindeman GJ and Visvader JE: Deciphering breast cancer: From biology to the clinic. Cell. 186:1708–1728. 2023. View Article : Google Scholar : PubMed/NCBI
3	Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME and Pietenpol JA: Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection. PLoS One. 11:e01573682016. View Article : Google Scholar :
4	Bianchini G, De Angelis C, Licata L and Gianni L: Treatment landscape of triple-negative breast cancer-expanded options, evolving needs. Nat Rev Clin Oncol. 19:91–113. 2022. View Article : Google Scholar
5	Waks AG and Winer EP: Breast cancer treatment: A review. JAMA. 321:288–300. 2019. View Article : Google Scholar : PubMed/NCBI
6	Loibl S, Poortmans P, Morrow M, Denkert C and Curigliano G: Breast cancer. Lancet. 397:1750–1769. 2021. View Article : Google Scholar : PubMed/NCBI
7	Cruwys S, Hein P, Humphries B and Black D: Drug discovery and development in idiopathic pulmonary fibrosis: The changing landscape. Drug Discov Today. 29:1042072024. View Article : Google Scholar : PubMed/NCBI
8	Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, Maher TM and Kolb M: Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 54:19001612019. View Article : Google Scholar : PubMed/NCBI
9	Peng M, Deng J and Li X: Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer. Mol Cancer. 23:2562024. View Article : Google Scholar : PubMed/NCBI
10	Yao H, Ren Y, Wu F, Cao L, Liu J, Yan M and Li X: The discovery of a novel AXL/triple angiokinase inhibitor based on 6-chloro-substituted indolinone and side chain methyl substitution inhibiting pancreatic cancer growth and metastasis. J Med Chem. 68:465–490. 2025. View Article : Google Scholar
11	Dong X, Wang L, Wang D, Yu M, Yang XJ and Cai H: Proteomic study on nintedanib in gastric cancer cells. PeerJ. 12:e167712024. View Article : Google Scholar : PubMed/NCBI
12	Quintela-Fandino M, Urruticoechea A, Guerra J, Gil M, Gonzalez-Martin A, Marquez R, Hernandez-Agudo E, Rodriguez-Martin C, Gil-Martin M, Bratos R, et al: Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study). British Br J Cancer. 111:1060–1064. 2014. View Article : Google Scholar
13	Adams CM, Mitra R, Xiao Y, Michener P, Palazzo J, Chao A, Gour J, Cassel J, Salvino JM and Eischen CM: Targeted MDM2 degradation reveals a new vulnerability for p53-inactivated triple-negative breast cancer. Cancer Discov. 13:1210–1229. 2023. View Article : Google Scholar : PubMed/NCBI
14	Yu Z, Dong X, Song M, Xu A, He Q, Li H, Ouyang W, Chouchane L and Ma X: Targeting UBR5 inhibits postsurgical breast cancer lung metastases by inducing CDC73 and p53 mediated apoptosis. Int J Cancer. 154:723–737. 2024. View Article : Google Scholar :
15	Li G, Lin SS, Yu Zl, Wu XH, Liu JW, Tu GH, Liu QY, Tang YL, Jiang QN, Xu JH, et al: A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer. Biochem Pharmacol. 206:1153292022. View Article : Google Scholar
16	Musa S, Amara N, Selawi A, Wang J, Marchini C, Agbarya A and Mahajna J: Overcoming chemoresistance in cancer: The promise of crizotinib. Cancers (Basel). 16:24792024. View Article : Google Scholar : PubMed/NCBI
17	Ramos H, Raimundo L and Saraiva L: p73: From the p53 shadow to a major pharmacological target in anticancer therapy. Pharmacol Res. 162:1052452020. View Article : Google Scholar
18	Bisso A, Collavin L and Del Sal G: p73 as a pharmaceutical target for cancer therapy. Curr Pharm Des. 17:578–590. 2011. View Article : Google Scholar : PubMed/NCBI
19	Rozenberg JM, Zvereva S, Dalina A, Blatov I, Zubarev I, Luppov D, Bessmertnyi A, Romanishin A, Alsoulaiman L, Kumeiko V, et al: Dual role of p73 in cancer microenvironment and DNA damage response. Cells. 10:35162021. View Article : Google Scholar : PubMed/NCBI
20	Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X, Lai L, Pei J and Li H: PharmMapper 2017 update: A web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 45(W1): W356–W60. 2017. View Article : Google Scholar
21	Wang Z, Wang HY, Chung CR, Horng JT, Lu JJ and Lee TY: Large-scale mass spectrometry data combined with demographics analysis rapidly predicts methicillin resistance in Staphylococcus aureus. Brief Bioinform. 22:bbaa2932021. View Article : Google Scholar
22	Sui X, Kong N, Ye L, Han W, Zhou J, Zhang Q, He C and Pan H: p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett. 344:174–179. 2014. View Article : Google Scholar
23	Kiri S and Ryba T: Cancer, metastasis, and the epigenome. Mol Cancer. 23:1542024. View Article : Google Scholar : PubMed/NCBI
24	Teufelsbauer M, Stickler S, Eggerstorfer MT, Hammond DC and Hamilton G: BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-436. Breast Cancer Res Treat. 208:89–101. 2024. View Article : Google Scholar :
25	Pham TH, Park HM, Kim J, Hong JT and Yoon DY: Interleukin-32θ triggers cellular senescence and reduces sensitivity to doxorubicin-mediated cytotoxicity in MDA-MB-231 Cells. Int J Mol Sci. 22:49752021. View Article : Google Scholar
26	Hwang SY, Park S and Kwon Y: Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther. 199:30–57. 2019. View Article : Google Scholar
27	van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J, Mathijssen RHJ, Danser AHJ and Lang NN: Hypertension and prohypertensive antineoplastic therapies in cancer patients. Circ Res. 128:1040–1061. 2021. View Article : Google Scholar : PubMed/NCBI
28	Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S and Chen Y: Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 15:1212022. View Article : Google Scholar :
29	Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, et al: Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov. 18:41–58. 2019. View Article : Google Scholar
30	Pan L, Cheng Y, Yang W, Wu X, Zhu H, Hu M, Zhang Y and Zhang M: Nintedanib ameliorates bleomycin-induced pulmonary fibrosis, inflammation, apoptosis, and oxidative stress by modulating PI3K/Akt/mTOR pathway in mice. Inflammation. 46:1531–1542. 2023. View Article : Google Scholar
31	Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003. View Article : Google Scholar : PubMed/NCBI
32	Tomuleasa C, Tigu AB, Munteanu R, Moldovan CS, Kegyes D, Onaciu A, Gulei D, Ghiaur G, Einsele H and Croce CM: Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduct Target Ther. 9:2012024. View Article : Google Scholar : PubMed/NCBI
33	Peuget S, Zhou X and Selivanova G: Translating p53-based therapies for cancer into the clinic. Nat Rev Cancer. 24:192–215. 2024. View Article : Google Scholar : PubMed/NCBI
34	Tuval A, Strandgren C, Heldin A, Palomar-Siles M and Wiman KG: Pharmacological reactivation of p53 in the era of precision anticancer medicine. Nat Rev Clin Oncol. 21:106–120. 2024. View Article : Google Scholar
35	Rodriguez Calleja L, Lavaud M, Tesfaye R, Brounais-Le-Royer B, Baud'huin M, Georges S, Lamoureux F, Verrecchia F and Ory B: The p53 family members p63 and p73 roles in the metastatic dissemination: Interactions with microRNAs and TGFβ pathway. Cancers (Basel). 14:59482022. View Article : Google Scholar
36	Sampath D, Calin GA, Puduvalli VK, Gopisetty G, Taccioli C, Liu CG, Ewald B, Liu C, Keating MJ and Plunkett W: Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood. 113:3744–3753. 2009. View Article : Google Scholar
37	Humbert M, Federzoni EA and Tschan MP: Distinct TP73-DAPK2-ATG5 pathway involvement in ATO-mediated cell death versus ATRA-mediated autophagy responses in APL. J Leukoc Biol. 102:1357–1370. 2017. View Article : Google Scholar : PubMed/NCBI
38	Browne IM, André F, Chandarlapaty S, Carey LA and Turner NC: Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Lancet Oncol. 25:e139–e151. 2024. View Article : Google Scholar : PubMed/NCBI
39	Zhu L, Li XX, Shi L, Wu J, Qian JY, Xia TS, Zhou WB, Sun X, Zhou XJ, Wei JF and Ding Q: Rapamycin enhances the sensitivity of ER-positive breast cancer cells to tamoxifen by upregulating p73 expression. Oncol Rep. 41:455–464. 2019.
40	Lu Z, Jiao D, Qiao J, Yang S, Yan M, Cui S and Liu Z: Restin suppressed epithelial-mesenchymal transition and tumor metastasis in breast cancer cells through upregulating mir-200a/b expression via association with p73. Mol Cancer. 14:1022015. View Article : Google Scholar : PubMed/NCBI
41	Goossens S, Vandamme N, Van Vlierberghe P and Berx G: EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET. Biochim Biophys Acta Rev Cancer. 1868:584–591. 2017. View Article : Google Scholar : PubMed/NCBI
42	Garinet S, Didelot A, Denize T, Perrier A, Beinse G, Leclere JB, Oudart JB, Gibault L, Badoual C, Le Pimpec-Barthes F, et al: Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC. Br J Cancer. 125:1544–1551. 2021. View Article : Google Scholar : PubMed/NCBI
43	Capdevila J, Carrato A, Tabernero J and Grande E: What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer? Crit Rev Oncol Hematol. 92:83–106. 2014. View Article : Google Scholar : PubMed/NCBI
44	Khalique S and Banerjee S: Nintedanib in ovarian cancer. Expert Opin Investig Drugs. 26:1073–1081. 2017. View Article : Google Scholar : PubMed/NCBI
45	Roth GJ, Binder R, Colbatzky F, Dallinger C, Schlenker-Herceg R, Hilberg F, Wollin SL and Kaiser R: Nintedanib: From discovery to the clinic. J Med Chem. 58:1053–1063. 2015. View Article : Google Scholar
46	Tu J, Xu H, Ma L, Li C, Qin W, Chen X, Yi M, Sun L, Liu B and Yuan X: Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells. Theranostics. 12:747–766. 2022. View Article : Google Scholar : PubMed/NCBI
47	Mukhopadhyay B, Singh S and Singh A: Utilizing nanomaterials for cancer treatment and diagnosis: An overview. Discov Nano. 19:2152024. View Article : Google Scholar : PubMed/NCBI